Please Wait
Applying Filters...
menu
    • menu
    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Rusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Sharp is a global leader in pharmaceutical packaging and clinical trial supply services.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    RLY-4008

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Elevar & Relay Therapeutics's Lirafugratinib Licensing for Cancer
    Elevar & Relay Therapeutics's Lirafugratinib Licensing for Cancer

    03 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/03/2990580/0/en/Elevar-Therapeutics-and-Relay-Therapeutics-Announce-Exclusive-Global-Licensing-Agreement-for-Lirafugratinib-in-FGFR2-Driven-Cholangiocarcinoma-and-Other-Solid-Tumors.html

    GLOBENEWSWIRE
    03 Dec 2024
    Share Share
    Lirafugratinib Elicits Durable Responses Across Several FGFR2+ Solid Tumors
    Lirafugratinib Elicits Durable Responses Across Several FGFR2+ Solid Tumors

    13 Oct 2023

    // ONCLIVE

    https://www.onclive.com/view/lirafugratinib-elicits-durable-responses-across-several-fgfr2-solid-tumors

    ONCLIVE
    13 Oct 2023
    Share Share
    Relay Therapeutics Announces RLY-4008 Data Showing Durable Responses Across Multiple FGFR2-Altered Solid Tumors
    Relay Therapeutics Announces RLY-4008 Data Showing Durable Responses Across Multiple FGFR2-Altered Solid Tumors

    12 Oct 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/10/12/2759649/0/en/Relay-Therapeutics-Announces-Initial-RLY-4008-lirafugratinib-Data-Demonstrating-Durable-Responses-Across-Multiple-FGFR2-Altered-Solid-Tumors.html

    GLOBENEWSWIRE
    12 Oct 2023
    Share Share